cbdMD shares surge 42.67% intraday after launching integrated regulatory science program and acquiring Bluebird Botanicals.

cbdMD surged 42.67% intraday following the announcement of a strategic regulatory science initiative and the completion of its acquisition of Bluebird Botanicals. The company integrated Bluebird’s assets, including a self-affirmed GRAS determination for full-spectrum hemp extract, to build a comprehensive regulatory platform. This move aims to strengthen its compliance framework and position cbdMD for evolving federal regulations, as highlighted by CEO Ronan Kennedy. The acquisition is projected to deliver 10% revenue growth, underscoring the company’s expansion in the hemp-derived wellness market. The intraday rally reflects investor optimism toward the strategic consolidation of scientific and regulatory resources, aligning with the company’s focus on long-term regulatory preparedness and market opportunities.